Nivolumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed cell death protein 1 (PD-1) receptor. It is primarily used in cancer immunotherapy to enhance the immune system's ability to recognize and attack tumor cells. Nivolumab is characterized by its ability to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are often exploited by cancer cells to evade immune detection. This blockade promotes T-cell activation and proliferation, leading to an increased anti-tumor response. Nivolumab is administered via intravenous infusion and is indicated for various malignancies, including melanoma, non-small cell lung cancer, and renal cell carcinoma. Its pharmacokinetics involve a long half-life, allowing for less frequent dosing schedules. Common side effects may include immune-related adverse events, such as pneumonitis, colitis, and endocrinopathies, due to enhanced immune activity. Overall, Nivolumab represents a significant advancement in cancer treatment, harnessing the body's immune system to combat malignancies effectively.

Nivolumab

946414-94-4: Nivolumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed cell death protein 1 (PD-1) receptor. It is primarily used in cancer immunotherapy to enhance the immune system's ability to recognize and attack tumor cells. Nivolumab is characterized by its ability to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are often exploited by cancer cells to evade immune detection. This blockade promotes T-cell activation and proliferation, leading to an increased anti-tumor response. Nivolumab is administered via intravenous infusion and is indicated for various malignancies, including melanoma, non-small cell lung cancer, and renal cell carcinoma. Its pharmacokinetics involve a long half-life, allowing for less frequent dosing schedules. Common side effects may include immune-related adverse events, such as pneumonitis, colitis, and endocrinopathies, due to enhanced immune activity. Overall, Nivolumab represents a significant advancement in cancer treatment, harnessing the body's immune system to combat malignancies effectively.

Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity. Cost-effective and quality-assured.

Monoclonal antibody against PD-1 checkpoint protein

CAS 946414-94-4

Nivolumab

Nivolumab

Ref: TM-T9907

Nivolumab - >10 mg/ml

Ref: 3D-BN164047